← back to search

Eva Bednarski

Rockefeller University · US
Area of research
Infectious Diseases · Molecular Biology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, vaccines and immunoinformatics approaches, and Immunotherapy and Immune Responses.
h-index
15
citations
3,000
works
30
NIH funding
primary concept
Biology
email

Recent publications

Coevolutionary constraints of Zika virus nonstructural protein 5 replication and interferon antagonism activities
bioRxiv (Cold Spring Harbor Laboratory) 2025cited by 1position: middledoi
Evolution of STAT2 resistance to flavivirus NS5 occurred multiple times despite genetic constraints
Nature Communications 2024cited by 13position: middledoi
SARS-CoV-2 vaccination, booster, and infection in pregnant population enhances passive immunity in neonates
Nature Communications 2023cited by 14position: middledoi
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Nature 2022cited by 322position: middledoi
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
Immunity 2022cited by 160position: middledoi
Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans
The Journal of Experimental Medicine 2022cited by 62position: middledoi
Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens
The Journal of Experimental Medicine 2022cited by 26position: middledoi
Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans
The Journal of Experimental Medicine 2022cited by 23position: middledoi
Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population
mBio 2022cited by 13position: firstdoi
Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants
The Journal of Experimental Medicine 2022cited by 11position: middledoi
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection
Open Forum Infectious Diseases 2022cited by 6position: middledoi
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Nature 2021cited by 798position: middledoi
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
Nature 2021cited by 301position: middledoi
High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
Nature 2021cited by 238position: middledoi
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
The Journal of Experimental Medicine 2020cited by 636position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Paul D. Bieniasz · Rockefeller University7 papers (2020–2023)Théodora Hatziioannou · Rockefeller University7 papers (2020–2023)Justin DaSilva · Rockefeller University5 papers (2021–2022)Alice Cho · Rockefeller University5 papers (2020–2022)Fabian Schmidt · Recordati (Ireland)5 papers (2020–2022)Christian Gaebler · Rockefeller University5 papers (2020–2022)Michel C. Nussenzweig · Rockefeller University5 papers (2020–2022)Marina Caskey · Rockefeller University5 papers (2020–2022)Zijun Wang · Rockefeller University4 papers (2020–2022)Frauke Muecksch · Heidelberg University4 papers (2020–2022)Dennis Schaefer-Babajew · Yale University3 papers (2021–2022)Anna Gazumyan · Rockefeller University3 papers (2020–2022)Yiska Weisblum · Rockefeller University3 papers (2020–2022)Katrina G. Millard · Rockefeller University3 papers (2022–2022)Martina Turroja · Rockefeller University3 papers (2022–2022)Tarek Ben Tanfous · Rockefeller University2 papers (2022–2022)Thiago Y. Oliveira · Universidade de São Paulo2 papers (2022–2022)Fengwen Zhang · National Center for Disease Control2 papers (2021–2022)Mila Janković · Rockefeller University2 papers (2022–2022)Brianna Johnson · Rockefeller University2 papers (2022–2022)